PMC:7144273 / 0-731 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T1","span":{"begin":43,"end":54},"obj":"UBERON:0001004;NCBITaxon:11886"},{"id":"T2","span":{"begin":55,"end":60},"obj":"NCBITaxon:10239"},{"id":"T3","span":{"begin":90,"end":98},"obj":"SP_7"},{"id":"T4","span":{"begin":192,"end":203},"obj":"UBERON:0001004"},{"id":"T5","span":{"begin":224,"end":235},"obj":"NCBITaxon:11118"},{"id":"T6","span":{"begin":250,"end":258},"obj":"SP_7"},{"id":"T7","span":{"begin":355,"end":366},"obj":"CL:0000134;UBERON:0003104"},{"id":"T8","span":{"begin":367,"end":371},"obj":"CL:0002540"},{"id":"T9","span":{"begin":373,"end":380},"obj":"CL:0000499;UBERON:0003891"},{"id":"T10","span":{"begin":389,"end":393},"obj":"DG_47"},{"id":"T11","span":{"begin":466,"end":477},"obj":"UBERON:0001004"},{"id":"T12","span":{"begin":546,"end":557},"obj":"UBERON:0001004;NCBITaxon:11886"},{"id":"T13","span":{"begin":558,"end":563},"obj":"NCBITaxon:10239"},{"id":"T14","span":{"begin":670,"end":681},"obj":"UBERON:0001004;NCBITaxon:11886"},{"id":"T15","span":{"begin":682,"end":687},"obj":"NCBITaxon:10239"},{"id":"T16","span":{"begin":689,"end":698},"obj":"NCBITaxon:7719"},{"id":"T26797","span":{"begin":43,"end":54},"obj":"UBERON:0001004;NCBITaxon:11886"},{"id":"T88846","span":{"begin":55,"end":60},"obj":"NCBITaxon:10239"},{"id":"T33319","span":{"begin":90,"end":98},"obj":"SP_7"},{"id":"T47763","span":{"begin":192,"end":203},"obj":"UBERON:0001004"},{"id":"T32062","span":{"begin":224,"end":235},"obj":"NCBITaxon:11118"},{"id":"T42644","span":{"begin":250,"end":258},"obj":"SP_7"},{"id":"T30365","span":{"begin":355,"end":366},"obj":"CL:0000134;UBERON:0003104"},{"id":"T92557","span":{"begin":367,"end":371},"obj":"CL:0002540"},{"id":"T88858","span":{"begin":373,"end":380},"obj":"CL:0000499;UBERON:0003891"},{"id":"T23043","span":{"begin":389,"end":393},"obj":"DG_47"},{"id":"T22777","span":{"begin":466,"end":477},"obj":"UBERON:0001004"},{"id":"T65786","span":{"begin":546,"end":557},"obj":"UBERON:0001004;NCBITaxon:11886"},{"id":"T40358","span":{"begin":558,"end":563},"obj":"NCBITaxon:10239"},{"id":"T6745","span":{"begin":670,"end":681},"obj":"UBERON:0001004;NCBITaxon:11886"},{"id":"T86660","span":{"begin":682,"end":687},"obj":"NCBITaxon:10239"},{"id":"T62576","span":{"begin":689,"end":698},"obj":"NCBITaxon:7719"}],"text":"Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19\nCurrent status of cell-based therapies for respiratory virus infections\n\nAbstract\nThe severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced l"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T1","span":{"begin":18,"end":22},"obj":"Body_part"},{"id":"T2","span":{"begin":117,"end":121},"obj":"Body_part"},{"id":"T3","span":{"begin":316,"end":320},"obj":"Body_part"},{"id":"T4","span":{"begin":382,"end":387},"obj":"Body_part"}],"attributes":[{"id":"A1","pred":"fma_id","subj":"T1","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A2","pred":"fma_id","subj":"T2","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A3","pred":"fma_id","subj":"T3","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A4","pred":"fma_id","subj":"T4","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19\nCurrent status of cell-based therapies for respiratory virus infections\n\nAbstract\nThe severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced l"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T1","span":{"begin":55,"end":71},"obj":"Disease"},{"id":"T2","span":{"begin":90,"end":98},"obj":"Disease"},{"id":"T3","span":{"begin":154,"end":170},"obj":"Disease"},{"id":"T4","span":{"begin":224,"end":248},"obj":"Disease"},{"id":"T5","span":{"begin":250,"end":258},"obj":"Disease"},{"id":"T6","span":{"begin":460,"end":495},"obj":"Disease"},{"id":"T7","span":{"begin":466,"end":495},"obj":"Disease"},{"id":"T8","span":{"begin":497,"end":501},"obj":"Disease"},{"id":"T9","span":{"begin":572,"end":576},"obj":"Disease"},{"id":"T10","span":{"begin":689,"end":698},"obj":"Disease"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A2","pred":"mondo_id","subj":"T2","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A3","pred":"mondo_id","subj":"T3","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A4","pred":"mondo_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"http://purl.obolibrary.org/obo/MONDO_0009971"},{"id":"A8","pred":"mondo_id","subj":"T8","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A9","pred":"mondo_id","subj":"T9","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A10","pred":"mondo_id","subj":"T10","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"}],"text":"Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19\nCurrent status of cell-based therapies for respiratory virus infections\n\nAbstract\nThe severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced l"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T1","span":{"begin":18,"end":22},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T2","span":{"begin":55,"end":60},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T3","span":{"begin":117,"end":121},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T4","span":{"begin":154,"end":159},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T5","span":{"begin":316,"end":320},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T6","span":{"begin":372,"end":387},"obj":"http://purl.obolibrary.org/obo/CL_0000499"},{"id":"T7","span":{"begin":558,"end":563},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T8","span":{"begin":682,"end":687},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19\nCurrent status of cell-based therapies for respiratory virus infections\n\nAbstract\nThe severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced l"}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T1","span":{"begin":466,"end":486},"obj":"Phenotype"}],"attributes":[{"id":"A1","pred":"hp_id","subj":"T1","obj":"http://purl.obolibrary.org/obo/HP_0002098"}],"text":"Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19\nCurrent status of cell-based therapies for respiratory virus infections\n\nAbstract\nThe severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced l"}

{"project":"LitCovid-sentences","denotations":[{"id":"T1","span":{"begin":0,"end":98},"obj":"Sentence"},{"id":"T2","span":{"begin":99,"end":170},"obj":"Sentence"},{"id":"T3","span":{"begin":172,"end":180},"obj":"Sentence"},{"id":"T4","span":{"begin":181,"end":315},"obj":"Sentence"},{"id":"T5","span":{"begin":316,"end":577},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19\nCurrent status of cell-based therapies for respiratory virus infections\n\nAbstract\nThe severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced l"}

{"project":"LitCovid-PubTator","denotations":[{"id":"2","span":{"begin":43,"end":71},"obj":"Disease"},{"id":"3","span":{"begin":90,"end":98},"obj":"Disease"},{"id":"19","span":{"begin":192,"end":203},"obj":"Species"}],"attributes":[{"id":"A3","pred":"tao:has_database_id","subj":"3","obj":"MESH:C000657245"},{"id":"A19","pred":"tao:has_database_id","subj":"19","obj":"Tax:12814"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19\nCurrent status of cell-based therapies for respiratory virus infections\n\nAbstract\nThe severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced l"}